Neurocrine Biosciences (NBIX) Debt to Equity (2018 - 2024)

Neurocrine Biosciences has reported Debt to Equity for 6 years, with the latest figure at $0.05 in Q1 2024.

• For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to $0.05; the trailing twelve-month figure through Mar 2024 stood at $0.05 (changed N/A YoY), and the FY2023 full-year result was $0.08, down 23.17% from the prior year.
• Debt to Equity for Q1 2024 stood at $0.05, down from $0.08 in the prior quarter.
• The five-year high for Debt to Equity was $0.53 in Q3 2020, with the low at $0.05 in Q1 2024.
• Historically, Debt to Equity has averaged $0.19 across 4 years, with a median of $0.1 in 2022.
• The largest YoY upside for Debt to Equity was 22.53% in 2023 against a maximum downside of 23.17% in 2023.
• Neurocrine Biosciences' Debt to Equity stood at $0.53 in 2020, then slumped by 81.23% to $0.1 in 2022, then dropped by 23.17% to $0.08 in 2023, then slumped by 32.47% to $0.05 in 2024.
• The last three Debt to Equity figures came in at $0.05 (Q1 2024), $0.08 (Q4 2023), and $0.08 (Q3 2023), per Business Quant data.